Literature DB >> 6105118

Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis.

A K Azad Khan, D T Howes, J Piris, S C Truelove.   

Abstract

Sulphasalazine is widely used in the maintenance treatment of ulcerative colitis but the optimum dose is not known. In the present study, 170 patients were allotted at random to three treatment groups, in which the daily dose was 1, 2 and 4 g respectively, and the trial period of treatment lasted for six months. A daily dose of 2 g was found to be much more efficacious than 1 g. A daily dose of 4 g was more efficacious than 2 g but at the price of fairly frequent symptomatic side-effects. Haematological abnormalities were observed at all dosage levels, but they occurred chiefly among the patients on 4 g daily. Both symptomatic and the haematological side-effects were usually associated with high concentrations of serum sulphapyridine and these high levels occurred chiefly among the slow acetylators. It is concluded that, for general use, a daily dose of 2 g sulphasalazine is satisfactory for the maintenance treatment of ulcerative colitis. If a patient does not do well on 2 g daily, it is worth trying a larger dose but in this case the patient's condition should be monitored by blood film, haemoglobin, MCV, and reticulocyte count.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6105118      PMCID: PMC1420362          DOI: 10.1136/gut.21.3.232

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  26 in total

1.  Sulphasalazine and salicylazosulphadimidine in ulcerative colitis.

Authors:  J H BARON; A M CONNELL; J E LENNARD-JONES; F A JONES
Journal:  Lancet       Date:  1962-05-26       Impact factor: 79.321

2.  A critical analysis of the use of salicylazosulfapyridine in chronic ulcerative colitis.

Authors:  C G MOERTEL; J A BARGEN
Journal:  Ann Intern Med       Date:  1959-11       Impact factor: 25.391

3.  Heinz-body anaemia due to salicylazosulphapyridine.

Authors:  A I SPRIGGS; R S SMITH; H GRIFFITH; S C TRUELOVE
Journal:  Lancet       Date:  1958-05-17       Impact factor: 79.321

4.  Metabolism of isoniazid in man as related to the occurrence of peripheral neuritis.

Authors:  H B HUGHES; J P BIEHL; A P JONES; L H SCHMIDT
Journal:  Am Rev Tuberc       Date:  1954-08

5.  Red cell abnormalities associated with sulphasalazine maintenance therapy for ulcerative colitis.

Authors:  R E Pounder; E R Craven; J S Henthorn; J M Bannatyne
Journal:  Gut       Date:  1975-03       Impact factor: 23.059

6.  Azulfidine agranulocytosis with bone marrow, megakaryocytosis, histiocytosis and plasmacytosis.

Authors:  K Jamshidi; T Arlander; M C Garcia; H W Windschitl; W R Swaim
Journal:  Minn Med       Date:  1972-06

7.  Determination of sulphapyridine and its metabolites in biological materials after administration of salicylazosulphapyridine.

Authors:  K A Hansson; M Sandberg
Journal:  Acta Pharm Suec       Date:  1973-03

8.  Letter: Hemolytic anemia as adverse reaction to salicylazosulfapyridine.

Authors:  E P Gabor
Journal:  N Engl J Med       Date:  1973-12-20       Impact factor: 91.245

9.  Adverse reactions to salicylazosulfapyridine (azulfidine) in the treatment of ulcerative colitis.

Authors:  J R Collins
Journal:  South Med J       Date:  1968-04       Impact factor: 0.954

10.  The metabolism of salicylazosulphapyridine in ulcerative colitis. I. The relationship between metabolites and the response to treatment in inpatients.

Authors:  K M Das; M A Eastwood; J P McManus; W Sircus
Journal:  Gut       Date:  1973-08       Impact factor: 23.059

View more
  52 in total

1.  Current medical therapy of inflammatory bowel disease.

Authors:  Kiron M Das; Sherif A Farag
Journal:  World J Gastroenterol       Date:  2000-08       Impact factor: 5.742

Review 2.  Drug therapy of ulcerative colitis.

Authors:  B Crotty; D P Jewell
Journal:  Br J Clin Pharmacol       Date:  1992-09       Impact factor: 4.335

3.  Is mesalamine safe?

Authors:  Kenneth W Schroeder
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-11

Review 4.  Sulphasalazine in ulcerative colitis: in memoriam?

Authors:  J Hayllar; I Bjarnason
Journal:  Gut       Date:  1991-05       Impact factor: 23.059

Review 5.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

6.  A double blind comparative study of sulphasalazine and hydroxychloroquine in rheumatoid arthritis: evidence of an earlier effect of sulphasalazine.

Authors:  I H Nuver-Zwart; P L van Riel; L B van de Putte; F W Gribnau
Journal:  Ann Rheum Dis       Date:  1989-05       Impact factor: 19.103

7.  Effect of reactive pharmacy intervention on quality of hospital prescribing.

Authors:  C J Hawkey; S Hodgson; A Norman; T K Daneshmend; S T Garner
Journal:  BMJ       Date:  1990-04-14

8.  Pharmacokinetics of sulfasalazine metabolites in rats following concomitant oral administration of riboflavin.

Authors:  V S Chungi; L W Dittert; L Shargel
Journal:  Pharm Res       Date:  1989-12       Impact factor: 4.200

9.  Desensitization for sulfasalazine-induced skin rash in a patient with ulcerative colitis.

Authors:  K Akahoshi; Y Chijiiwa; T Kabemura; H Okabe; Y Akamine; H Nawata
Journal:  J Gastroenterol       Date:  1994-12       Impact factor: 7.527

10.  The value of 5-aminosalicylic acid in inflammatory bowel disease for patients intolerant or allergic to sulphasalazine.

Authors:  I P Donald; S P Wilkinson
Journal:  Postgrad Med J       Date:  1985-12       Impact factor: 2.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.